By: J. Kerger MD
ESMO 2016 not only reflected the increasing interest in oncology by attracting close to 20.000 participants, but also featured the presentation of several important abstracts that may lead to changes in the daily clinical management of gynaecological cancers. This was especially the case for ovarian carcinomas.
(BELG J MED ONCOL 2016;10(8):301–07)
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
